Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091931 · ClinicalTrials.gov registry record
Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting
A clinical trial, sponsored by Pathnostics.
- Completed
- Registry status
- 3,308
- Enrollment target
NCT05091931: Completed study, sponsored by Pathnostics.
NCT05091931 is a clinical trial that has completed, run by Pathnostics. The registered enrollment target is 3,308 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091931 has completed, sponsored by Pathnostics.
- COMPLETED
- Registry status
- 3,308 participants
- Enrollment target
Study Summary
This prospective, multicenter, comparative cohort observational study is to determine if Guidance® UTI pathway compared to traditional diagnostic pathways reduces the rates of empiric antibiotic therapy, adverse events, and improves therapeutic accuracy of treatment
Primary Outcome
The percentage of outpatients seen for suspected UTI started on empiric treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,308 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2024-09-19 |
What the finished NCT05091931 record still lists
NCT05091931 is an observational study that tracks outcomes without assigning an intervention. Its 3,308 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05091931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05091931 about?
NCT05091931 is a clinical study titled "Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting". This prospective, multicenter, comparative cohort observational study is to determine if Guidance® UTI pathway compared to traditional diagnostic pathways reduces the rates of empiric antibiotic therapy, adverse events, and improves therapeutic accuracy of treatment
What is the current status of trial NCT05091931?
This trial is currently completed. The enrollment target is 3,308 participants. The study started on 2022-03-28. Estimated completion is 2024-09-19.
Who is sponsoring clinical trial NCT05091931?
This trial is sponsored by Pathnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI